tulaven
ceva santé animale - tulathromycin - antibakteriální látky pro systémové použití - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. přítomnost onemocnění ve stádu by měla být stanovena před metafylaktickou léčbou. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. přítomnost onemocnění ve stádu by měla být stanovena před metafylaktickou léčbou. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovce: léčba počátečních stadií infekční podkožní kůže (hniloba chodidel) spojená s virulentním dichelobacter nodosus vyžadujícím systémovou léčbu.
rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastická činidla - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
calrecia 100mmol/l infuzní roztok
fresenius medical care deutschland gmbh, bad homburg array - 5599 dihydrÁt chloridu vÁpenatÉho - infuzní roztok - 100mmol/l - chlorid vÁpenatÝ
cinacalcet reddy 30mg potahovaná tableta
reddy holding gmbh, augsburg array - 17229 cinakalcet-hydrochlorid - potahovaná tableta - 30mg - cinakalcet
cinacalcet reddy 60mg potahovaná tableta
reddy holding gmbh, augsburg array - 17229 cinakalcet-hydrochlorid - potahovaná tableta - 60mg - cinakalcet
cinacalcet reddy 90mg potahovaná tableta
reddy holding gmbh, augsburg array - 17229 cinakalcet-hydrochlorid - potahovaná tableta - 90mg - cinakalcet
cinacalcet sandoz 30mg potahovaná tableta
sandoz s.r.o., praha array - 17229 cinakalcet-hydrochlorid - potahovaná tableta - 30mg - cinakalcet
cinacalcet sandoz 60mg potahovaná tableta
sandoz s.r.o., praha array - 17229 cinakalcet-hydrochlorid - potahovaná tableta - 60mg - cinakalcet
cinacalcet sandoz 90mg potahovaná tableta
sandoz s.r.o., praha array - 17229 cinakalcet-hydrochlorid - potahovaná tableta - 90mg - cinakalcet